FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
MGRX holds $481,281 in cash and burns about $380,262/quarter from operations, giving an estimated runway of 3.8 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for MGRX free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-03-20 | Cohen Jacob D. |
Purchase | $0 |
| 2026-03-20 | Cohen Jacob D. |
Purchase | $0 |
| 2026-03-20 | Cohen Jacob D. |
Purchase | $0 |
| 2026-03-20 | Cohen Jacob D. |
Purchase | $0 |
| 2026-03-20 | Cohen Jacob D. |
Sale | $0 |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for MGRX and 2 more tickers of your choice.
Create Free Account →